CENTRAL DATA COLLECTION CENTER (CDCC) CONTINUED FOLLOW-UP OF PLCO

PLCO中心数据协调中心（CDCC）是前列腺、肺、结直肠癌和卵巢癌（PLCO）癌症筛查试验的延伸。为了降低成本，扩建后的数据收集站由国家癌症研究所（NCI）管理，而不是原来的10个PLCO筛选中心。PLCO的参与者被邀请转到发展协调中心继续积极跟进。其他参与者同意通过肿瘤登记搜索被动跟踪PLCO站点。PLCO旨在确定前列腺癌、肺癌、结直肠癌和卵巢癌的筛查是否能降低这些癌症的死亡率。此外，PLCO还收集了储存在PLCO生物库中的诊断前和诊断后的生物样本，以及来自问卷调查的流行病学数据。这些数据是前沿分子流行病学研究的宝贵资源。这项研究以这种精简的方式进行扩展，以增加资源的价值。该研究将通过收集额外的风险和生活方式信息，包括老年人常见的药物使用和医疗状况，继续更新关键暴露数据。此外，疾控中心还将收集额外的临床数据和选定癌症的肿瘤组织，如结肠癌和卵巢癌。PLCO癌症筛查试验的扩展通过试验中累积的癌症事件数量的大幅增加，提高了PLCO资源的价值，加强了试验进一步阐明筛查对癌症死亡率的长期影响的能力，并提供了收集额外暴露数据和扩大PLCO内现有肿瘤病理资源的最终机会。

The PLCO Central Data Coordinating Center (CDCC) is an extension of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. To reduce costs, the extension has one data collection site under the direction of the National Cancer Institute (NCI) rather than the original ten PLCO Screening Centers. PLCO participants were invited to be transferred to the CDCC for continued, active follow up. Other participants agreed to be passively followed at the PLCO sites through tumor registry searches. PLCO was designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers. In addition, PLCO has a collection of pre- and post-diagnostic biological samples stored in the PLCO Biorepostory, and epidemiological data from questionnaires. These data are a valuable resource for cutting-edge molecular epidemiologic research. The study was extended in this streamlined fashion to increase the value of the resource. The study will continue to update key exposure data by collecting additional risk and lifestyle information, including medication use and medical conditions that are common in older adults. Also, the CDCC will collect additional clinical data and tumor tissue of selected cancers, such as that of the colon and ovaries. This extension of the PLCO Cancer Screening Trial enhances the value of the PLCO resources through the substantial increase in the number of incident cancers accrued within the Trial, strengthens the Trial's ability to clarify further the long-term effects of screening on cancer mortality, and provides a final opportunity to collect additional exposure data and expand the existing tumor pathological resource within the PLCO.